Related Experiment Video
Updated: Jun 2, 2025
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.2K
Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection fraction.
Benjamin Sasko1,2,3, Theodoros Kelesidis4, Sawa Kostin5
1Ruhr-University of Bochum, Medical Department II, Marien Hospital Herne, Bochum, Germany. b.sasko@uk-brandenburg.de.
Summary
Reduced HDL antioxidant function is linked to heart failure with preserved ejection fraction (HFpEF). This finding suggests that improving HDL function may be a potential therapeutic target for early HFpEF treatment.
Area of Science:
- Cardiology
- Biochemistry
- Internal Medicine
Background:
- Heart failure (HF) is a growing global health concern with increasing prevalence in Western populations due to cardiovascular risk factors.
- Oxidative stress and inflammation are key contributors to the pathophysiology of heart failure with preserved ejection fraction (HFpEF).
- Previous research indicates a link between dysfunctional high-density lipoprotein (HDL) and HF, but the specific role of oxidized HDL in HFpEF remains unclear.
Purpose of the Study:
- To investigate the association between reduced HDL antioxidant function and the presence of HFpEF.
- To determine if oxidized HDL levels are an independent predictor of HFpEF in patients with suspected heart failure.
Main Methods:
- A cross-sectional observational study involving 366 patients with suspected heart failure.
- Assessment of HDL antioxidant function using a cell-free biochemical assay measuring HDL-lipid peroxide content (HDLox), normalized by HDL-C levels (nHDLox).
- Statistical analysis included multivariate models to identify independent predictors of HFpEF, adjusting for various clinical and biochemical factors.
Main Results:
- Patients with HFpEF exhibited significantly higher mean relative levels of nHDLox compared to those without heart failure.
- nHDLox was identified as an independent predictor of HFpEF in both basic and full multivariate models (p < 0.05).
- A 1-SD increase in nHDLox was associated with a 67% increased risk of HFpEF (p = 0.02).
Conclusions:
- HDL antioxidant function is demonstrably reduced in patients diagnosed with HFpEF.
- Targeting and improving HDL function presents a promising therapeutic strategy for the early management of heart failure.
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314